Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Receives Additional Delisting Notice from Nasdaq, Initiates Stock Split

SAN FRANCISCO, Jan. 15 - Lynx Therapeutics said today that has received notice from Nasdaq that it is in additional danger of delisting.


Nasdaq determined that Lynx was not in compliance with Nasdaq's audit committee requirements for continued listing. This notice comes on the heels of Lynx stock falling below Nasdaq's minimum bid price for continued listing.


Lynx has been granted a hearing before a Nasdaq panel to review the audit committee's decision.


Lynx said it was appointing an independent director to its audit committee at its next regularly scheduled board of directors meeting and that it expects to be in compliance with Nasdaq's audit committee requirements as defined by Nasdaq's Marketplace Rule 4350(d)(2).


Lynx also announced today that it will be initiating a reverse split of its stock. A 1-for-7 reverse split of its common stock was approved by its board of directors and stockholders and will take effect January 16. The split will reduce the number of common stock outstanding from about 32.5 million to 4.6 million, according to Lynx. Lynx will temporarily trade under the symbol LYNXD until reverting back to LYNX around February 13, the company said.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.